LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Surmodics to Participate in Upcoming Investor Conferences in March

March 08, 2023 | Last Trade: US$39.70 0.26 -0.65

EDEN PRAIRIE, Minn. / Mar 08, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:

The 33rd Oppenheimer Annual Healthcare Conference, which is being held virtually March 13‑15, 2023.

  • Management will present on Wednesday, March 15, at 10:40 a.m. ET (9:40 a.m. CT).

The Sidoti Small-Cap Conference, which is being held virtually March 22-23, 2023.

  • Management will participate in 1x1 meetings with investors on Wednesday, March 22, and Thursday, March 23. There will be no formal presentation.

To access a live webcast of the presentation, go to “Events & Presentations” under the “Investors” section of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” A replay of the webcast will be archived on the website for the following 90 days.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.

Astria Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB